A Phase 1 Study to evaluate the Pharmacokinetics, Safety and Tolerability of AP02 (Nintedanib Solution for Inhalation) Delivered via the PARI eFlow Nebulizer System (registered) in Normal Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis or Progressive Fibrosing Interstitial Lung Disease
Latest Information Update: 26 May 2025
At a glance
- Drugs Nintedanib (Primary)
- Indications Lung disorders; Lung injury
- Focus Adverse reactions
- Sponsors Avalyn Pharma
Most Recent Events
- 20 May 2025 According to Avalyn Pharma Inc. Media release, data from this study presented at the American Thoracic Society (ATS) International Conference 2025 being held May 16-21, 2025, in San Francisco, CA.
- 06 May 2025 According to Avalyn Pharma Inc. Media release, topline data from this study will be presented at the American Thoracic Society (ATS) 2025 International Conference being held May 16-21, 2025, at the Moscone Center in San Francisco, CA.
- 30 Mar 2023 According to an Avalyn Pharma media release, the company plans to present more detailed findings from the study at a medical meeting later in 2023.